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Traumatic brain injury (TBI) causes transient increases and subsequent decreases in 
brain glucose utilization. The underlying molecular pathways are orchestrated processes 
and poorly understood. In the current study, we determined temporal changes in cortical 
and hippocampal expression of genes important for brain glucose/lactate metabolism 
and the effect of a known neuroprotective drug telmisartan on the expression of these 
genes after experimental TBI. Adult male C57BL/6J mice (n = 6/group) underwent sham 
or unilateral controlled cortical impact (CCI) injury. Their ipsilateral and contralateral 
cortex and hippocampus were collected 6 h, 1, 3, 7, 14, 21, and 28 days after injury. 
Expressions of several genes important for brain glucose utilization were determined by 
qRT-PCR. In results, (1) mRNA levels of three key enzymes in glucose metabolism [hexo 
kinase (HK) 1, pyruvate kinase, and pyruvate dehydrogenase (PDH)] were all increased 
6 h after injury in the contralateral cortex, followed by decreases at subsequent times in 
the ipsilateral cortex and hippocampus; (2) capillary glucose transporter Glut-1 mRNA 
increased, while neuronal glucose transporter Glut-3 mRNA decreased, at various times 
in the ipsilateral cortex and hippocampus; (3) astrocyte lactate transporter MCT-1 mRNA 
increased, whereas neuronal lactate transporter MCT-2 mRNA decreased in the ipsilat-
eral cortex and hippocampus; (4) HK2 (an isoform of hexokinase) expression increased 
at all time points in the ipsilateral cortex and hippocampus. GPR81 (lactate receptor) 
mRNA increased at various time points in the ipsilateral cortex and hippocampus. These 
temporal alterations in gene expression corresponded closely to the patterns of impaired 
brain glucose utilization reported in both TBI patients and experimental TBI rodents. The 
observed changes in hippocampal gene expression were delayed and prolonged, when 
compared with those in the cortex. The patterns of alterations were specific to different 
Figure 1 | Schematized brain glucose utilization among capillaries, 
astrocytes and neurons. HK, hexokinase; PK, pyruvate kinase; PDH, 
pyruvate dehydrogenase; Glut-1, capillary glucose transporters 1; Glut-3, 
neuronal glucose transport 3; MCT-1, astrocyte monocaboxylate (lactate) 
transporters 1; MCT-2, neuronal monocaboxylate (lactate) transporters 2. 
GPR81 (G protein-coupled receptor 81 or hydrocarboxylic acid receptor 1, 
serve as lactate receptor when lactate is used for signaling molecule).
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brain regions and exhibited different recovery periods following TBI. Oral administration 
of telmisartan (1 mg/kg, for 7 days, n = 10 per group) ameliorated cortical or hippocam-
pal mRNA for Glut-1/3, MCT-1/2 and PDH in CCI mice. These data provide molecular 
evidence for dynamic alteration of multiple critical factors in brain glucose metabolism 
post-TBI and can inform further research for treating brain metabolic disorders post-TBI.
Keywords: gene expression, glucose metabolism, lactate, hexokinase, gPr81, angiotensin ii aT1 receptor, 
telmisartan,  traumatic brain injury
inTrODucTiOn
Glucose is an essential fuel for maintaining cellular functions. 
In particular, the brain uses glucose and its related intermedi-
ate metabolites as energetic substrates to support its functions. 
Under most normal and pathological conditions, brain glucose 
utilization is well preserved by complex mechanisms, regardless 
of peripheral glucose fluctuations.
Following traumatic brain injury (TBI), various brain tis-
sues undergo two types of injuries. The primary injury results 
from direct mechanical damage to the brain. Subsequently, 
secondary injury elicits a series of pathophysiological cascade, 
including edema, increased intracranial pressure, hemorrhage, 
and decreased cerebral blood flow. Cellular processes during the 
secondary injury phase involve excessive release of excitatory 
neurotransmitters, activation of ion channels, mitochondrial 
dysfunction, hypoxia, and inflammation (1, 2), all leading to 
degradation of cellular structures, apoptosis (3), and affecting 
brain glucose requirements and utilization (4, 5). In fact, TBI 
consistently triggers transient increases and prolonged decreases 
in brain glucose utilization, as assessed by brain imaging in both 
TBI patients and experimental animals (6–12).
Our current understanding of molecular processes related 
effects of TBI on brain glucose utilization is limited. This limita-
tion poses a critical barrier in developing potential therapeutic 
strategies for TBI management. Among more than 300 currently 
registered human clinical trials targeting to drug intervention 
of TBI, there are fewer than 10 trials targeted to normalize 
brain glucose utilization, and the intervention compounds 
used in these trials are limited to insulin or glucose/lactate 
(13). In contrast, several classes of FDA-approved pharmaco-
logical agents improve peripheral tissue glucose utilization, 
with clearly identified mechanisms. A better understanding of 
molecular mechanisms related to brain glucose utilization after 
TBI will accelerate investigations of these agents regarding their 
potential similar effect(s) in the posttraumatic-injured brain.
Brain glucose utilization requires glucose transport and 
metabolism, as schematized in Figure 1. Glucose transporters 
(Glut-1 and Glut-3) transport glucose from capillaries to astro-
cytes and/or neurons (14, 15). Several rate-limiting enzymes 
play critical roles in glucose metabolism, such as hexokinase 
1 (HK1), pyruvate kinase (PK), and pyruvate dehydrogenase 
(PDH). Additionally, neurons use lactate as an energy sub-
strate to produce ATP (16, 17). Lactate can be produced by 
glycogenolysis in astrocytes and transported to neurons via 
monocaboxylate transporters (MCT-1 and MCT-2) (15, 18, 19). 
HK2 (an isoform of hexokinase) and GPR81 (lactate receptor) 
are also important in brain glucose metabolism, especially in 
the injured brain. HK2 expression has been identified in the 
outer membrane of mitochondria in most brain area and is 
related to abnormal glycolysis during hypoxia and apoptosis 
(20). Lactate-activated GPR81 affects several biological path-
ways in the injured brain, including brain glucose metabolism 
(21–23). The expression of these enzymes and transporters in 
various brain tissues is vulnerable to primary and secondary 
brain injuries.
Several prior reports suggest how various types of TBI influ-
ence expression of these enzymes and transporters individually 
(24–26). In addition, gene array and proteomics studies have 
examined the expression of large numbers of genes or proteins, 
including the aforementioned enzymes/transporters, pre-
dominantly within a single brain region and/or at a single time 
point after experimental TBI (27–30). Because brain glucose 
metabolism is an orchestrated interplay, more fundamental 
questions remain to be answered. How does TBI simultane-
ously influence gene expression of multiple key enzymes/trans-
porters that span the gamut of glucose-associated metabolic 
processes? Also, how does TBI-mediated gene expression vary 
TaBle 1 | Brain glucose/lactate utilization related genes.
gene name TagMan gene expression iD Function
Hk1 Mm00439344_m1 Hexokinase 1
PK Mm00834102_gH Pyruvate kinase
PDH Mm00499323_m1 Pyruvate dehydrogenase
Slc2a1 Mm00441480_m1 Glut-1: capillary glucose 
transporter
Slc2a3 Mm00441483_m1 Glut-3: neuronal glucose 
transporter
Slc16a1 Mm01306379_m1 MCT-1: astrocyte lactate 
transport 
Slc16a7 Mm00441442_m1 MCT-2: neuronal lactate  
transporter
GPR81 Mm00558586_s1 lactate receptor
Hk2 Mm00443385_m1 Hexokinase isoform 2
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in diverse brain regions during progression of and recovery 
from TBI?
In the current studies, we used a controlled cortical impact 
(CCI) injury mouse model of TBI to investigate: (1) temporal 
changes in gene expression of selected enzymes and transporters 
known to be critical for brain glucose utilization, (2) whether a 
known neuroprotective agent, telmisartan, ameliorates altera-
tions in expression of the abovementioned genes following CCI. 
Telmisartan is an FDA-approved drug and was originally used 
for treatment of hypertension, based upon its activity as an 
angiotensin II AT1 receptor blocker (ARB). Telmisartan also 
activates peroxisome proliferator-activated receptor gamma 
(PPARγ), which improves peripheral tissue glucose utilization 
(31). Neuroprotective effects of telmisartan have recently been 
reported and are thought to be mediated in part by activating 
PPARγ (32–35). Because of the complex pathogenesis of TBI, 
optimized therapies for TBI should target several coexisting 
pathological mechanisms (36). Considering pleiotropic actions 
of telmisartan on TBI and glucose metabolism, we examined 
its effects on expression of genes that regulate to brain glucose 
utilization in a TBI mouse model.
In study 1, we examined expression of a set of genes related 
to glucose metabolism at multiple time points to determine 
if the temporal changes in mRNA expression were related to 
the temporal changes in brain glucose metabolism after brain 
injury. These points are chosen to represent early and second-
ary injuries phases following TBI. In study 2, we examined 
if gene expression affected by TBI would be ameliorated by 
telmisartan at a single time point that was selected based on 
results from study 1. Cortex and hippocampus are the two 
brain regions that are directly injured or located immediately 
underneath the injured cortex in our CCI mouse model. Thus, 
tissues from these two regions contralateral and ipsilateral 
to the injury were selected for measuring expression of the 
aforementioned genes.
Our ultimate goal is to develop much needed new therapeu-
tic options for TBI. Data from the current studies will inform 
subsequent mechanistic studies and broaden our selection of 
other drugs for their potential role on impaired brain glucose 
metabolism following TBI.
MaTerials anD MeThODs
animals and cci injury
All animal protocols were approved by the Georgetown 
University Animal Care and Use Committee and followed 
National Institutes of Health standards.
Healthy, intact male C57BL/6J mice, aged 8  weeks (Jackson 
Laboratories, Bar Harbor, ME, USA) were group housed at 
room temperature of 22 ± 1°C with a 12-h light/dark cycle and 
ad  libitum access to food and water. Mice were habituated to 
the environmental conditions for 7  days. The CCI injury was 
induced over the parietal cortex as previously described, and 
was considered to elicit moderate TBI (37). Briefly, the brain is 
injured by rigid impactor to an intact dura exposed following a 
craniectomy on the left cortex. The following parameters were 
used to control impact severity: an impact velocity of 5.25 m/s, 
a dwell time of 0.1 s, an impact depth of 2.0 mm, and an impac-
tor tip with 3.5 mm diameter. All mice were anesthetized with 
isoflurane (induction at 4% and maintenance at 2%) evaporated 
in oxygen and administered through a nose mask. Anesthesia 
depth was monitored by assessing respiration rate and pedal 
withdrawal reflexes. The mice were placed on a custom-made 
stereotaxic frame with a built-in heating bed that maintained 
body temperature at 37°C. After injury, the incisions were closed 
with staples, anesthesia was terminated, and the animals were 
placed in heated cages to maintain normal core temperature 
for 45 min postinjury. Sham-injured mice underwent the same 
procedures, including anesthesia, stereotaxic mounting, skin and 
fascia reflection, and incision closing with staples, but a cranial 
window was not introduced as we consider this to be part of the 
primary injury sequence in the CCI model.
In experiment 1, mice were decapitated without isoflurane 
anesthesia at seven different time points (6 h, 1, 3, 7, 14, 21, and 
28 days) after CCI or sham injury (n = 6 per group). In experiment 
2, mice were divided into vehicle or telmisartan groups after CCI 
or sham injury (n = 10/group, a total of four groups). Telmisartan 
(Sigma-Aldrich, 1 mg/kg, dissolved in 1% DMSO diluted in dis-
tilled water) or vehicle (1% DMSO diluted in distilled water) were 
administered by oral gavage at a volume of 5 mL/kg. Telmisartan 
was administrated 1 h post-CCI or sham injury, and once per day 
for the following 6 days. The experiment was ended 7 days after 
CCI or sham injury.
For both CCI- and sham-injured mice, the ipsilateral and 
contralateral parietal cortex and hippocampus were dissected 
and immediately placed in RNAlater® Solution (Ambion, 
Thermo Fisher Scientific) and stored at −20°C for total RNA 
extraction.
The following verifications were performed to ensure 
accuracy of the real-time PCR TaqMan® method. (1) The same 
samples were tested with or without DNase treatment for each 
of the nine target genes (Table 1) to eliminate possible genomic 
DNA contamination. (2) Standard curves (range from 0.122 
to 250  ng/µL total RNA) were assessed for all nine genes to 
verify the sufficiency and specificity of PCR amplifications for 
each target gene. The slopes of standard curves were all within 
a 3.0–3.6 range, and coefficients of determination (R2) were all 
TaBle 2 | Housekeeping genes tested.






Cyclophilin Custom designed (40)
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larger than 0.99, as required by the TaqMan® real-time PCR 
assay (3). Because target gene expression must be normalized 
using endogenous housekeeping genes, it was essential that the 
endogenous control genes used were not altered by TBI. We 
tested six different candidate endogenous housekeeping genes 
(Table 2) in samples collected at different time points after CCI 
to ensure that the expression level of selected housekeeping 
gene was stable and not altered by the injury. The variances in 
expression levels among those samples were calculated for each 
candidate housekeeping gene (data not shown). The gene with 
the smallest variance (cyclophilin) was selected for use as the 
endogenous housekeeping gene. Our results were consistent 
with a prior publication regarding selection of an endogenous 
housekeeping gene in mice after experimental TBI (38). To 
eliminate possible error caused by sample pipetting and differ-
ences in RNA quantity and efficiency of reverse transcription 
for each sample, we established a multiplex q-PCR method for 
all genes listed in Table 1. Each tested gene was measured in 
the separate reaction alone, and with cyclophilin, to verify that 
there was no significant primer dimer formation. The detailed 
real-time PCR TaqMan® condition was the same as the proto-
col provided by Applied Biosystems (39). The probes for each 
target gene and cyclophilin were labeled with FAM and VIC, 
respectively.
After the qRT-PCR method was verified as described above, 
total RNA was extracted from the dissected tissues using the 
Trizol reagent following the manufacturer’s protocol, and 
expression of nine different genes (Table 1) in cortex and hip-
pocampus both ipsilateral and contralateral to the injury were 
measured by the multiplex q-PCR method. A comparative Ct 
(ddCt) method was used to determine gene expression levels 
for each sample.
statistical analysis
Data are presented as mean values ± SEM. SAS 9.2 was used for 
all analyses. P < 0.05 was considerate statistically significant.
For study 1, results were expressed as the percentage change 
over their corresponding control samples, which were collected 
at corresponding time points and corresponding (ipsilateral or 
contralateral) sites from sham-injured mice. Data were analyzed 
by two-way ANOVA with treatment (Sham vs. TBI) and time 
post-CCI as two independent factors. Because observed temporal 
changes varied for different genes and injured sides, the time 
frames used for calculating TBI effects differed, as specified in 
the Results section. For those genes that exhibited opposite trends 
of alterations at 6 h, compared with all other time points following 
CCI, one-way ANOVA was used to compare TBI and sham group 
at the 6 h time point only.
For study 2, data were analyzed by T-test. Comparison was 
made within the same injury sides (contralateral or ipsilateral) 
and the same drug treatment (vehicle or telmisartan).
resulTs
expression of genes That encode critical 
enzymes for glucose Metabolism
Hexokinase 1, PK, and PDH are three rate-limiting enzymes 
that play critical roles in glucose metabolism (Figures 1 and 2). 
mRNA expressions of all three of these enzymes were signifi-
cantly altered after CCI (Figure 2). However, the alterations dif-
fered in regard to brain region, site of injury, and time postinjury. 
mRNA levels of HK1, PK, and PDH all increased early (6 h) after 
injury in the contralateral cortex, and all decreased at various 
subsequent time points in the ipsilateral cortex and hippocam-
pus. Moreover, the observed decreases in the ipsilateral side 
were kinetically delayed in the hippocampus when compared 
to those in the cortex. For HK1, the decreases occurred from 
day 1 to day 7 in the cortex (P < 0.05) and from day 3 to day 28 
in the hippocampus (P < 0.05). For PK, the decreases occurred 
from 6 h to day 14 in the cortex (P < 0.05) and from day 7 to 
day 28 in the hippocampus (P < 0.05). For PDH, the decreases 
occurred from day 1 to day 7 in the cortex (P < 0.01) and from 
day 7 to day 28 in the hippocampus (P  <  0.05). In contrast 
to these ipsilateral decreases, the expression of HK1, PK, and 
PDH in the contralateral cortex all increased 6  h postinjury 
(P < 0.05 for HK1, PK, and P < 0.01 for PDH) and returned 
to the level of sham controls by day 1 after injury. The only 
exception was the level of PDH mRNA in the contralateral 
cortex, which also had transient increase at day 3 postinjury 
(P < 0.05). As expected, in the contralateral hippocampus, none 
of the three genes exhibited altered expression at any time point 
following CCI. Together, these results demonstrated that the 
alterations observed on the ipsilateral side recovered in the 
cortex within days after injury, but persisted significantly longer 
in the hippocampus.
expression of genes That encode critical 
glucose Transporters
Glut-1 is a capillary glucose transporter and Glut-3 is a neuronal 
glucose transporter. In the contralateral cortex and hippocam-
pus, expression of both Glut-1 and Glut-3 mRNAs increased 
at 6  h and returned to sham levels by day 1 following injury 
(P  <  0.05) (Figure  3). However, in the ipsilateral cortex and 
hippocampus, CCI-affected Glut-1 and Glut-3 gene expression 
in an opposite manner. Glut-1 increased from 6 h to day 7 in 
the cortex (P < 0.01) and from 6 h to day 21 in the hippocam-
pus (P  <  0.01). Glut-3 decreased from day 3 to day 7 in the 
cortex (P < 0.05) and from day 3 to day 28 in the hippocampus 
(P < 0.01), despite transient increases at 6 h (P < 0.01 for both 
cortex and hippocampus). These data suggest that CCI affects 
the mRNAs of these two glucose transporters in opposite direc-
tions, based on their cellular locations. In general, capillary 
Figure 2 | Hexokinase (HK), pyruvate kinase (PK), and pyruvate dehydrogenase (PDH) mRNA levels in the cortex and hippocampus measured at different time 
points postcontrolled cortical impact (post-CCI). Data are mean ± SEM (n = 3–6 per group at each time point for each group). #: P < 0.05, contralateral cortex of 
injured mice compared with the corresponding tissue of sham-injured mice at indicated single time points. Solid brackets indicate the comparison between 
ipsilateral side of cortex/hippocampus of CCI mice and the corresponding tissue obtained from sham operated mice.
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located Glut-1 mRNA increased, while neuronal located Glut-3 
decreased.
expression of genes That encode critical 
lactate Transporters
MCT-1 is an astrocyte lactate transporter and MCT-2 is a 
neuronal lactate transporter. MCT-1 mRNA increased substan-
tially in both cortex and hippocampus, regardless of injury side 
(P < 0.01) (Figure 4). In contrast to these increases in MCT-1, 
MCT-2 mRNA decreased, and the duration and timing of the 
decreases were distinctive to injury sides. On the contralateral 
side, decreases in MCT-2 were only observed at day 1 postin-
jury for cortex (P  <  0.05) and hippocampus (P  <  0.01). On 
the ipsilateral side, decreases in MCT-2 were persistent from 
6  h to day 28 postinjury in both cortex (P  <  0.01) and hip-
pocampus (P <  0.01). We also observed a trend to decreased 
MCT-2 mRNA returning to sham level in the cortex (time effect 
P  <  0.01 by two way ANOVA), but not in the hippocampus. 
Figure 3 | Glut-1and Glut-3 mRNA levels in the cortex and hippocampus measured at different time points postcontrolled cortical impact (post-CCI). Data are 
mean ± SEM (n = 3–6 per group at each time point for each group). #: P < 0.05, contralateral cortex/hippocampus of injured mice compared with corresponding 
tissue obtained from sham-operated mice at indicated single time points. **, P < 0.01, ipsilateral cortex/hippocampus of injured mice compared with corresponding 
tissue obtained from sham-operated mice at indicated single time points. Solid brackets indicate the comparison between the ipsilateral side of cortex/hippocampus 
from CCI mice and corresponding tissue obtained from sham-operated mice.
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Therefore, similar to glucose transporters, CCI also affected 
these two lactate transporters’ mRNA in opposite directions 
based on their cellular locations. In general, mRNA of MCT-1 
located in astrocytes increased, while mRNA of MCT-2 located 
in neurons decreased.
expression of genes That encode hK2 
and lactate receptor gPr81
Hexokinase 2 mRNA was dramatically increased at all time 
points in both cortex and hippocampus, regardless of injury sides 
(P < 0.01), except at 6 h time point on the contralateral side of 
hippocampus (Figure 5). The increased HK2 expression peaked 
at day 3 or day 7 postinjury on the ipsilateral cortex and hip-
pocampus, respectively. Notably, among all the genes examined, 
the ipsilateral increases of HK2 mRNA were the most dramatic: 
600% and 1,200% above the sham levels in cortex and hippocam-
pus, respectively.
Controlled cortical impact also increased expression of 
GPR81 mRNA in an injury side and time specific manner. On 
the ipsilateral side, GPR81 mRNA levels increased from 6 h to day 
28 in the cortex (P < 0.01) and from day 7 to day 28 in the hip-
pocampus (P < 0.05) post-TBI. On the contralateral side, GPR81 
mRNA increased only at day 28 postinjury in the hippocampus 
(P < 0.05), but not in the cortex.
Telmisartan selectively ameliorated  
cci-affected gene expression of  
glut-1/3, McT-1/2, and PDh
From study 1, we found CCI increased gene expression for 
capillary glucose transporter Glut-1 and astrocyte lactate 
transporter MCT-1 and decreased gene expression for neuronal 
glucose transporter Glut-3 and lactate transporter MCT-2 in the 
ipsilateral side of both cortex and hippocampus (Figures 3 and 
4). Such effects were confirmed in study 2 (Figures  3 and 4). 
However, telmisartan gavage at a dosage of 1 mg/kg for 7 days 
partially reversed the alterations of Glut-1 and Glut-3 in the 
ipsilateral cortex and hippocampus (Figure 6). For lactate trans-
porters, telmisartan prevented increased MCT-1 expression in 
the contralateral, but not ipsilateral, hippocampus (Figure 7B). 
Compared to MCT-1, the decreased gene expression of MCT-2 
Figure 4 | Monocaboxylate transporter (MCT)-1 and MCT-2 mRNA levels in the cortex and hippocampus measured at different time points postcontrolled cortical 
impact (post-CCI). Data are mean ± SEM (n = 3–6 per group at each time point). # or ## P < 0.05 or P < 0.01, contralateral cortex or hippocampus of injured mice 
compared with corresponding tissue obtained from sham-operated mice at indicated single time points. Solid brackets indicate the comparison between the 
ipsilateral side of the cortex or hippocampus from CCI-injured mice and the corresponding tissue obtained from sham-operated mice. Dashed brackets indicate the 
comparison between contralateral sides of the cortex or hippocampus from CCI-injured mice and the same sides of corresponding tissue obtained from sham-
operated mice.
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was small and were prevented by telmisartan in the ipsilateral 
hippocampus (Figure 7D).
We also measured HK1, PK, PDH, HK2, and GPR81 gene 
expression in the contralateral and ipsilateral sides of both 
cortex and hippocampus. Telmisartan partially reversed the 
CCI-induced changes in ipsilateral hippocampal PDH mRNA 
levels, but not other alterations caused by CCI, 7 days postinjury 
(Table 3).
DiscussiOn
The temporal alterations in gene expression we observed in these 
brain areas corresponded closely to transient early increases 
and subsequent decreases in brain glucose utilization reported 
in humans and experimental animals following various types of 
TBI injury (6–12, 41, 42). Six hours after CCI, mRNA levels for 
two glucose transporters (Glut-1 and Glut-3) and three critical 
enzymes (HK1, PK, and PDH) were all significantly increased in 
contralateral brain area. These transient increases might reflect 
the need for short-term increases in brain glucose utilization 
immediately following TBI reported previously (6, 7). At various 
subsequent time points, we observed decreased mRNA expres-
sion for HK1, PK, and PDH in the ipsilateral cortex and hip-
pocampus. HK1, PK, and PDH protein levels have been reported 
to decrease following different types of TBI (29, 43, 44). Thus, our 
observed decreases in mRNA of three critical enzymes agree with 
previously reported relative protein changes and the prolonged 
decreases in brain glucose metabolism.
Interestingly, mRNA for both glucose and lactate transporters 
changed in opposite directions, depending on the locations of 
these transporters. Glut-1, predominantly expressed in capil-
laries (14, 15), increased; whereas neuronal Glut-3 decreased 
in the ipsilateral cortex and hippocampus. Similarly, lactate 
transporter MCT-1, predominantly located in astrocytes (15, 
18, 19), increased; whereas neuronal lactate transporter MCT-2 
decreased in the ipsilateral cortex and hippocampus. These find-
ings suggest that the sustained impairments in brain glucose uti-
lization following TBI may be neuron-specific, despite stimulated 
Figure 5 | An isoform of hexokinase (HK2) and GPR81 mRNA levels in the cortex and hippocampus measured at different time points postcontrolled cortical 
impact (post-CCI). Data are mean values ± SEM (n = 3–6 per group at each time point). Solid brackets indicate the comparison between ipsilateral sides of the 
cortex or hippocampus from CCI-injured mice and the corresponding tissue obtained from sham-operated mice. Dashed brackets indicate the comparison between 
contralateral sides of the cortex or hippocampus from CCI-injured mice and the same side of corresponding tissue obtained from sham-injured mice.
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expressions of glucose and lactate transporters in capillary and 
astrocytes. One possible explanation might relate to neuronal 
susceptibility to death and neuronal loss immediately after injury 
of the ipsilateral hemisphere. Further research on cell-specific 
glucose metabolism appears warranted to enhance our under-
standing of TBI impaired brain glucose utilization.
Changes in hippocampal gene expression were both delayed 
and prolonged, when compared with those in the cortex. This 
finding agrees with clinical observations that the hippocam-
pus exhibits prolonged impairments in glucose metabolism 
when compared with other brain regions, as detected by 
positron emission tomography (11). For all three key glucose 
metabolism-related enzymes tested in the current study, their 
mRNA alterations returned to or toward normal shortly after 
injury in the cortex. In contrast, alterations of the same three 
genes persisted for the duration of study in the hippocampus. 
The underlying molecular mechanisms responsible for these 
kinetic and tissue-specific changes likely involve multiple 
factors. One possible factor is permeability of gap junctions, 
which are intercellular channels connecting the cytoplasm of 
two cells. These neuronal gap junctions are critically impor-
tant in the secondary neuronal death following CCI (45). The 
observation that the gap junctions in the hippocampus are sig-
nificantly more permeable than those in the cortex (46) might 
explain why the hippocampus appears to be more vulnerable to 
harmful molecules resulted from the secondary injury follow-
ing TBI. Our data also suggest that the delayed and prolonged 
alteration of these genes in hippocampus may be a cause of 
the corresponding protracted effects of TBI on memory. Such 
hypothesis needs to be confirmed by further studies on longer 
periods after TBI.
The finding of dramatically increased HK2 mRNA expres-
sion both contralateral and ipsilateral to the injured cortex 
and hippocampus was unexpected. HK2 is an isoform of 
hexokinase. Unlike HK1, the temporal changes of HK2 
mRNA expression suggest hypoxia and apoptosis related to 
abnormal glycolysis (20). Up-regulation of HK2 mRNA is 
typically associated with aerobic glycolysis rather than oxida-
tive phosphorylation to generate ATP (47), possibly due to the 
activation of neuroinflammatory responses in microglia and 
Figure 6 | Telmisartan ameliorated controlled cortical impact (CCI)-affected gene expression for Glut-1 and Glut-3. mRNA of capillary glucose transporter Glut-1 
(a,B) and neuronal glucose transporter Glut-3 (c,D) were increased or decreased 7 days after CCI in ipsilateral sides of cortex and hippocampus of mice (n = 10/
group). Telmisartan (1 mg/kg) revised these changes. *P < 0.05 traumatic brain injury (TBI) vs. Sham.
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astrocytes (48). Moreover, HK2 expression was associated with 
poor prognosis and worse overall survival of glioma patients 
(47, 40, 49). Following CCI, HK2 expression peaked at day 
3 or day 7 postinjury and remained two-fold elevated above 
sham levels at the end of study. These dynamic features and 
relevance to the recovery process suggest that HK2 mRNA 
may serve as a biomarker to monitor the progress of injury and 
recover following TBI. Further studies will determine whether 
detection of HK2 mRNA in neuron-specific exosomes isolated 
from peripheral blood can serve as a candidate biomarker for 
monitoring the progress of TBI.
GPR81 is a G protein-coupled receptor activated by lactate 
(22, 50, 51). Brain lactate concentrations are significantly 
increased following TBI (52). The increased lactate can serve 
both as an alternative brain energetic fuel, and as a signaling 
molecule affecting several biological pathways in the injured 
brain (22, 23, 53). Overexpression of GPR81 has been shown to 
increase cell vulnerability to ischemic injury, whereas inhibition 
of GPR81 prevented neuronal cell death and reversed brain 
ischemia-induced apoptosis (53). Thus, GPR81 antagonism has 
been suggested as a possible therapeutic strategy for the treat-
ment of cerebral ischemia (54). Of note, GPR81 also participates 
in lactate related neuronal protection initiated by acute organ 
injury (21, 22, 55). Our findings suggest that use of lactate as 
a supplementary fuel following brain injury (56, 57) may have 
complicated consequences. The timing, benefits and harm of such 
approach requires further investigation.
In brief, CCI-induced alterations in gene expression were 
specific for the injury side and postinjury time. One possible 
explanation is that the secondary injury may radiate from initial 
injury site like a wave to adjacent tissues. Thus, in general, altera-
tions contralateral to the injury were less severe than those ipsilat-
eral to the injury, except at 6 h. Also, alterations in hippocampal 
gene expression were both delayed and prolonged compared with 
those in the cortex. These results were of interest because they 
allow visualization of changes that code most important factors 
in glucose metabolism.
Telmisartan and other ARBs are strongly neuroprotective 
in many rodent models of brain disorders, including TBI 
(35, 58–62) In experimental TBI, telmisartan reduced inflam-
mation and neuronal injury and protected cognition (35, 
63–71), effects mediated in part by activating PPARγ (32–35). 
Telmisartan has also been assessed in patients with Alzheimer’s 
disease in an NIH approved clinical trial (72). Although 
telmisartan improved glucose utilization in human peripheral 
tissues and olfactory tracts (73, 74), its effects on normalizing 
Figure 7 | Telmisartan ameliorated controlled cortical impact (CCI)-affected gene expression for MCT-1 and MCT-2. mRNA of astrocyte lactate transporter MCT-1 
(a,B) and neuronal lactate transporter MCT-2 (c,D) were increased or decreased 7 days after CCI in ipsilateral or contralateral sides of cortex and hippocampus of 
mice (n = 10/group). Telmisartan (1 mg/kg) revised these changes. *P < 0.05 traumatic brain injury (TBI) vs. Sham.
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glucose metabolic-related pathways post-TBI have not been 
reported. In the current study, we observed that telmisartan 
improved some, but not all alterations in gene expression 
7  days post-TBI. Primarily, CCI-induced changes in mRNAs 
for glucose/lactate transporters impaired by CCI were partially 
improved by telmisartan, as well as mRNA for one of three genes 
encodes critical enzymes related to glucose metabolism. These 
improvements were only detected when comparison was made 
between telmisartan-treated Sham vs. TBI groups, not between 
vehicle-treated TBI vs. telmisartan-treated TBI groups. How 
these improvements interact with other known neuroprotective 
pathways require further investigation.
The current findings represent an initial step in our research 
and need to be complemented, in further studies, with data 
integrating gene expression with protein levels and glucose 
utilization. We did not examine the temporal alterations in 
behavior, biochemistry or histology in this mouse model, 
as those data have been previously published by our group 
(37, 58–60). It should also be noted that longitudinal recovery 
from TBI-induced brain metabolic depression has been related 
to recovery of behavioral dysfunction assessed by the Morris 
Water Maze performance (12).
In summary, we measured temporal changes in gene 
expression of crucial factors that span the interacting pathways 
associated with glucose metabolism in two key brain regions 
after CCI in adult mice. The observed temporal alterations in 
gene expression corresponded closely to temporal alterations 
in brain glucose utilization reported in TBI patients and 
experimental animals (6–12). TBI-mediated changes in gene 
expressions persisted longer in hippocampal vs. cortical tissues 
and some of those alterations in gene expression were amelio-
rated by the neuroprotective agent telmisartan. These results 
will inform subsequent more comprehensive investigations on 
development of pharmacological interventions that can target 
the dynamic interplay in brain glucose metabolic disorders 
following TBI.
TaBle 3 | Gene expression of HK1, PK, PDH, HK2, and GPR81 measured 7 days post-TBI.
Tissue Drug Treat hK1 PK PDh hK2 gPr-81
Contralateral cortex Vehicle Sham 1.40 ± 0.06 4.96 ± 0.18 4.75 ± 0.37 8.2 ± 0.81 10.31 ± 1.32
TBI 1.32 ± 0.05 5.04 ± 0.22 4.62 ± 0.26 14.3 ± 4.3** 15.94 ± 3.29
Telmisartan Sham 1.40 ± 0.06 4.52 ± 0.42 4.65 ± 0.25 7.9 ± 0.43 10.53 ± 1.14
TBI 1.31 ± 0.06 4.59 ± 0.20 4.83 ± 0.31 11.4 ± 0.9** 11.74 ± 1.28
Ipsilateral cortex Vehicle Sham 1.54 ± 0.12 3.46 ± 0.26 4.78 ± 0.54 6.5 ± 0.60 7.06 ± 2.02
TBI 1.35 ± 0.03* 3.77 ± 0.18 4.36 ± 0.34 53.3 ± 11.3** 16.79 ± 1.7**
Telmisartan Sham 1.53 ± 0.10 3.72 ± 0.23 4.55 ± 0.35 13.6 ± 6.16 7.92 ± 1.19
TBI 1.34 ± 0.06* 3.64 ± 0.29 4.83 ± 0.46 34.1 ± 5.2** 15.73 ± 1.9**
Contralateral hippocampus Vehicle Sham 1.86 ± 0.10 5.90 ± 0.51 9.79 ± 0.88 13.9 ± 1.57 22.13 ± 3.23
TBI 1.92 ± 0.10 6.58 ± 0.40 10.36 ± 0.59 32.5 ± 4.4** 27.40 ± 3.84
Telmisartan Sham 1.97 ± 0.46 6.04 ± 0.31 9.78 ± 0.70 9.9 ± 1.21 23.30 ± 2.56
TBI 2.09 ± 0.06 6.03 ± 0.34 10.50 ± 0.52 27.2 ± 2.7** 31.43 ± 5.17
Ipsilateral hippocampus Vehicle Sham 1.77 ± 0.10 6.75 ± 0.34 7.77 ± 0.45 11.7 ± 0.56 17.65 ± 2.54
TBI 1.57 ± 0.07* 6.63 ± 0.39 5.84 ± 0.67* 62.3 ± 10.6** 31.47 ± 6.16*
Telmisartan Sham 1.80 ± 0.46 6.25 ± 0.51 7.70 ± 0.34 11.0 ± 0.41 19.40 ± 2.66
TBI 1.58 ± 0.06* 6.61 ± 0.27 6.36 ± 0.32 75.6 ± 5.4** 27.08 ± 4.57*
Data are presented as relative ratio of tested gene/cyclophilin and shown as mean ± SE (n = 9–10 per group).
*P < 0.05 compared with Sham within the same drug treatment in the same brain area.
**P < 0.01 compared with Sham within the same drug treatment in the same brain area.
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